Literature DB >> 19144502

Objective: remission of depression in primary care The Oreon Study.

Marc Ansseau1, Koen Demyttenaere, Jan Heyrman, André Migeotte, Sophie Leyman, Annick Mignon.   

Abstract

OBJECTIVE: Treatment of depression should result in the absence of symptoms, i.e. remission, in order to restore the functional status of the patient and reduce the risk for relapse. The study assessed the current remission rates in primary care and determined the influencing factors.
METHODS: 10 consecutive depressive patients treated by antidepressants for at least 3 months and not more than 12 months were screened by each investigator. Remission rates were defined using the Hamilton-Depression scale 7 items (score of 3 or less) as well as the Carroll self rating scale (score of 7 or less). In addition, patients completed the Sheehan Disability Scale (SDS). Initial severity of depression, type of treatment and socio-economic factors were collected.
RESULTS: 292 general practitioners screened a total of 2630 patients. Results indicated low remission rates: 28.3% according to the clinician and 17.1% according to the patient. Absence of remission was associated with higher impairment in work, social and family life. The most frequently reported residual symptoms in nonremitters were general somatic symptoms (92%), depressed mood (92%), psychic anxiety (91%) and impaired work and activities (89%). No differences were observed in remission rates between men and women. Remission rates were significantly lower in patients living alone as compared to those living in couple or family (25.1% vs 30.2%, p=0.03), in patients with lower education (21.3% vs 32.3%, p<0.001), in patients speaking French as compared to Dutch (24.0% vs 34.0% p<0.001), and unemployed patients compared to patients having an occupation (17.1% vs 39.0%, p<0.001). Higher initial severity and number of previous episodes decreased remission rates (p<0.001).
CONCLUSION: This study shows low remission rates in depressed patients treated in general practice. The absence of remission is associated with impairment in work, social and family life. Special attention should be given to identify patients who do not reach remission.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19144502     DOI: 10.1016/j.euroneuro.2008.10.003

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  9 in total

1.  fMRI activation in the amygdala and the orbitofrontal cortex in unmedicated subjects with major depressive disorder.

Authors:  Jennifer D Townsend; Nicole K Eberhart; Susan Y Bookheimer; Naomi I Eisenberger; Lara C Foland-Ross; Ian A Cook; Catherine A Sugar; Lori L Altshuler
Journal:  Psychiatry Res       Date:  2010-08-13       Impact factor: 3.222

Review 2.  Evidence for the management of adolescent depression.

Authors:  R Eric Lewandowski; Mary C Acri; Kimberly E Hoagwood; Mark Olfson; Greg Clarke; William Gardner; Sarah Hudson Scholle; Sepheen Byron; Kelly Kelleher; Harold A Pincus; Samantha Frank; Sarah M Horwitz
Journal:  Pediatrics       Date:  2013-09-16       Impact factor: 7.124

3.  Clinical validity of a population database definition of remission in patients with major depression.

Authors:  Antoni Sicras-Mainar; Milagrosa Blanca-Tamayo; Laura Gutiérrez-Nicuesa; Jordi Salvatella-Pasant; Ruth Navarro-Artieda
Journal:  BMC Public Health       Date:  2010-02-11       Impact factor: 3.295

4.  Relationship of residual mood and panic-agoraphobic spectrum phenomenology to quality of life and functional impairment in patients with major depression.

Authors:  Antonella Benvenuti; Paola Rucci; Simona Calugi; Giovanni B Cassano; Mario Miniati; Ellen Frank
Journal:  Int Clin Psychopharmacol       Date:  2010-03       Impact factor: 1.659

5.  Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials.

Authors:  Stuart A Montgomery; Carl P Gommoll; Changzheng Chen; William M Greenberg
Journal:  CNS Spectr       Date:  2014-06-05       Impact factor: 3.790

6.  Comparative Study of Cognitive Function Between Treatment-Resistant Depressive Patients and First-Episode Depressive Patients.

Authors:  Dongping Rao; Guiyun Xu; Zenghong Lu; Huiwei Liang; Kangguang Lin; Muni Tang
Journal:  Neuropsychiatr Dis Treat       Date:  2019-12-09       Impact factor: 2.570

7.  Clinical predictors associated with full remission versus episode of major depressive disorder outpatients: the experience at a teaching hospital in Taiwan.

Authors:  Mei-Yu Yeh; Yu Lee; Su-Ching Sung; Tao-Hsin Tung
Journal:  BMC Psychiatry       Date:  2014-09-24       Impact factor: 3.630

8.  Remission in Depression and Associated Factors at Different Assessment Times in Primary Care in Chile.

Authors:  Veronica Vitriol; Alfredo Cancino; Carlos Serrano; Soledad Ballesteros; Soledad Potthoff
Journal:  Clin Pract Epidemiol Ment Health       Date:  2018-03-26

9.  Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials.

Authors:  Susan Kornstein; Cheng-Tao Chang; Carl P Gommoll; John Edwards
Journal:  Int Clin Psychopharmacol       Date:  2018-07       Impact factor: 1.659

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.